These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30976998)

  • 1. Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.
    Abo YN; Refsum E; Mackie N; Lyall H; Tudor-Williams G; Foster C
    Clin Drug Investig; 2019 Jun; 39(6):585-590. PubMed ID: 30976998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naïve and -experienced patients.
    Brehm TT; Franz M; Hüfner A; Hertling S; Schmiedel S; Degen O; Kreuels B; Schulze Zur Wiesch J
    Medicine (Baltimore); 2019 Aug; 98(32):e16721. PubMed ID: 31393378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
    Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
    J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
    O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
    J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of integrase inhibitors in a real-life setting.
    Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
    J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on raltegravir and the development of new integrase strand transfer inhibitors.
    Shamroe CL; Bookstaver PB; Rokas KE; Weissman SB
    South Med J; 2012 Jul; 105(7):370-8. PubMed ID: 22766666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
    Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
    Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.
    Modica S; Rossetti B; Lombardi F; Lagi F; Maffeo M; D'Autilia R; Pecorari M; Vicenti I; Bruzzone B; Magnani G; Paolucci S; Francisci D; Penco G; Sacchini D; Zazzi M; De Luca A; Di Biagio A
    HIV Med; 2019 Feb; 20(2):137-146. PubMed ID: 30461149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
    Ndashimye E; Avino M; Olabode AS; Poon AFY; Gibson RM; Li Y; Meadows A; Tan C; Reyes PS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Arts EJ
    J Antimicrob Chemother; 2020 Dec; 75(12):3525-3533. PubMed ID: 32853364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to HIV integrase strand transfer inhibitors in Argentina: first interim survey.
    Cecchini DM; Castillo S; Copertari G; Lacal V; Rodriguez CG; Cassetti I
    Rev Esp Quimioter; 2019 Jun; 32(3):263-267. PubMed ID: 31037930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
    Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
    HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction.
    Rahangdale L; Cates J; Potter J; Badell ML; Seidman D; Miller ES; Coleman JS; Lazenby GB; Levison J; Short WR; Yawetz S; Ciaranello A; Livingston E; Duthely L; Rimawi BH; Anderson JR; Stringer EM;
    Am J Obstet Gynecol; 2016 Mar; 214(3):385.e1-7. PubMed ID: 26928154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
    Chouchana L; Beeker N; Treluyer JM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir (DTG)-containing regimens after receiving raltegravir (RAL) or elvitegravir (EVG): Durability and virological response in a large Italian HIV drug resistance network (ARCA).
    Rusconi S; Adorni F; Tau P; Borghi V; Pecorari M; Maserati R; Francisci D; Monno L; Punzi G; Meraviglia P; Paolucci S; Di Biagio A; Bruzzone B; Mancon A; Micheli V; Zazzi M;
    J Clin Virol; 2018 Aug; 105():112-117. PubMed ID: 29957545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
    Rossetti B; Fabbiani M; Di Carlo D; Incardona F; Abecasis A; Gomes P; Geretti AM; Seguin-Devaux C; Garcia F; Kaiser R; Modica S; Shallvari A; Sönnerborg A; Zazzi M;
    J Antimicrob Chemother; 2021 Aug; 76(9):2394-2399. PubMed ID: 34212176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability of HIV integrase inhibitors.
    Lee FJ; Carr A
    Curr Opin HIV AIDS; 2012 Sep; 7(5):422-8. PubMed ID: 22886031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.